The Auxiliary Diagnostic Value of a Novel Wearable Electrocardiogram-Recording System for Arrhythmia Detection: Diagnostic Trial

Shaomin Zhang, Hong Xian, Yi Chen, Yue Liao, Nan Zhang, Xinyu Guo, Ming Yang*† and Jinhui Wu*†

The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China

Background: AMAZFIT®, a novel wearable electrocardiogram (ECG)-recording system is used for the measurement, acquisition, and storage of single-lead cardiac waveforms for adults. The aim of the study was to evaluate the accuracy of AMAZFIT® for diagnosing arrhythmia in older patients.

Methods: From May to December 2019, we recruited 291 elderly individuals with an average age of 78±10 years old, and 41.9% women. All cardiac waveforms were obtained from the AMAZFIT® which included limb and chest leads. Two trained technicians reviewed all ECG data to determine cardiac rhythm using standard diagnostic criteria. We evaluated the accuracy of AMAZFIT® for identifying arrhythmia by comparing the sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and positive and negative likelihood ratios with those of a standard 12-lead ECG.

Results: Of the 291 participants, 197 older adults had arrhythmias, including AF (n = 119), first-degree AVB (n = 28), PACs (n = 25), and PVCs (n = 28). Three of these participants had arrhythmias of AF and PVCs. Chest lead data from 100% and limb lead data from 4.7% of the participants were analyzed. An evaluation of AMAZFIT® for atrial fibrillation (AF) reported a sensitivity, specificity, PPV, NPV PLR, and negative likelihood ratio (NLR) of 93.28, 95.35, 93.28, 95.35, 20.06, and 0.07%, respectively. AMAZFIT® also demonstrated excellent sensitivity for premature atrial contractions (PACs) (84.00%) and premature ventricular contractions (PVCs) (89.29%). However, the device demonstrated a low sensitivity for first-degree atrioventricular block (32.14%).

Conclusions: The AMAZFIT® showed significantly higher sensitivity and specificity for AF, PACs, and PVCs. This portable ECG-recording device based on an algorithm has a potential auxiliary diagnostic value for identifying arrhythmia compared with a standard 12-lead ECG device.

Keywords: arrhythmia, atrial fibrillation, AMAZFIT, detection, diagnostic trial
INTRODUCTION

The incidence and prevalence rates of arrhythmias, which include atrial fibrillation (AF), premature heart beats, and conduction block, are showing increasing trends, particularly in the elderly population. AF is one of the world’s most common serious cardiac rhythm problems. Arrhythmias are significantly associated with increased morbidity and higher mortality (1–3). The prevalence of arrhythmia is doubled in people over 40 years of age (4, 5). Earlier identification of AF may reduce the risk of stroke and other consequences. A diagnostic challenge is that AF is often asymptomatic (6). An invasive cardiac monitoring strategy is the gold-standard for high-risk patients (7, 8). Insertable leadless cardiac monitors are associated with higher AF detection rates; however, this strategy is not easily adopted due to its inconvenience, and invasive characteristics, among other reasons.

Wearable arrhythmia detection devices are becoming increasingly popular (9). There is an increasing interest in the use of smartwatch-based technology for AF detection, with some initial data indicating that these devices may be used for population-level AF screening. While there is high clinician interest in the diagnostic precision from these devices, there is a paucity of data that evaluates their accuracy for the diagnosis of arrhythmia (10).

Some smartwatches such as the Apple Watch, Kadia Band, Kadia Mobile, and Simband, have been used for cardiac rhythm analyses (11–14). Unlike these smartwatches, the AMAZFIT® (Huami Corporation, Anhui, China) can collect single-lead cardiac waveforms from the chest lead, which could be used for the measurement, acquisition, and storage of single-lead cardiac waveforms for adults. We aimed to evaluate the accuracy of the AMAZFIT® as a detection tool for the diagnosis of arrhythmia in older patients.

METHODS

This was a diagnostic trial. A 12-lead ECG was used as the gold-standard to evaluate the diagnostic value of a wearable dynamic ECG recorder (AMAZFIT®) for the detection of arrhythmia.

Study Population

We continuously invited patients (≥ 65 years of age) who were admitted to the Center of Gerontology and Geriatrics of West China Hospital from May to December 2019 who had a complaint of palpitation to participate in this study. The exclusion criteria were as follows: (1) a history of cognitive impairment (MMSE < 10 score); (2) a history of skin disorders around the wrist or chest; (3) those who had unstable vital signs; and (4) those who refused to participate. All patients gave written informed consent.

Data Collection

For all participants, after obtaining informed consent, baseline demographic, clinical comorbidities and medications were abstracted from their medical records by a trained staff member. The arrhythmia and the type of arrhythmia were determined according to the results of conventional 12-lead ECG.

All participants were asked to hold the AMAZFIT® wearable dynamic ECG recorder (Model No DLA31003; Production Permit No 20180010; Product Registration No 201822100012) on their wrist and chest wall for 1 min, during which time the pulse waveform was recorded in the AMAZFIT® Health App. Participants wore an AMAZFIT® on either wrist to collect limb lead data, which was firmly secured above the ulnar styloid. To collect chest lead data, the AMAZFIT® was applied with medical electrode stickers. AMAZFIT® is attached to the left side of the chest wall as shown in Figure 1. The mobile phone software was connected to the AMAZFIT®, and then the chest patch mode was selected to start the measurement.

At the same time, all participants were simultaneously acquiring regular 12-lead ECG waveforms. The 12-lead electrode has 10 electrode heads, which are placed on the human chest C1, C2, C3, C4, C5, C6, and the limbs RA(right arm), LA(left arm), RL(right leg), LL(left leg) positions, thereby obtaining 12-lead ECG(I, II, III, aVR, aVL, aVF, V1, V2, V3, V4, V5, and V6). For both techniques, the high pass and low pass filters used for ECG signal processing were respectively 0.6 and 25 Hz for 12-lead ECG and 0.67 and 40 Hz for the AMAZFIT®. Two trained ECG technicians reviewed all ECG data that was collected by AMAZFIT® to determine heart rhythm using standard criteria. In case of disagreement about the diagnosis between the reviewers, an electrophysiologist was consulted. The comparison between conventional 12-lead ECG and chest lead ECG data collected by AMAZFIT® are shown in Figure 2.

Statistical Analysis

Statistical analyses were performed using the SPSS 22.0 software program. Continuous variables were described as means ± standard deviations and categorical variables were described as numbers (percentages). We then calculated test characteristics, including sensitivity, specificity, accuracy, PPV, NPV, positive likelihood ratio and negative likelihood ratio for the AMAZFIT® wearable dynamic ECG recorder detection for AF, first-degree AVB, PACs, and PVCs compared with the expert reviewer diagnosis (criterion standard) of sinus rhythm based on 12-lead ECG.

RESULTS

The characteristics of the 291 participants included in our study are shown in Table 1. The mean age of the cohort was 78 ± 10 years, and 41.9% were women. A total of 119 participants were included in the AF cohort. There was no atrial flutter cases in the AF cohort. The other arrhythmia cohort included 81 participants with: first-degree atrioventricular block (n = 28), PACs (n = 25), and PVCs (n = 28), while the normal ECG cohort included 94 participants.

We used AMAZFIT® to collect cardiac waveform data for all participants, including limb lead and chest lead data. Chest lead data were successfully collected from 291 participants, while limb lead data were successfully collected from 43 participants. A total of 291 (100%) chest lead data recordings
FIGURE 1 | AMAZFIT® location diagram. (A): wrist (B): chest wall.

FIGURE 2 | Comparison of the waveforms from ECG and from AMAZFIT®. (A): sinus rhythm; (B): AF; (C): PACs; (D): PVCs; (E): first-degree AVB. AF, arterial fibrillation; PACs, premature arterial contractions; PVCs, premature ventricular contractions; AVB, atrioventricular block.
TABLE 1 | Baseline characteristics of the study population.

|                  | AF  | AVB | PACs | PVCs | Normal ECG |
|------------------|-----|-----|------|------|-------------|
|                  | \(n = 119\) | \(n = 28\) | \(n = 25\) | \(n = 28\) | \(n = 94\) |
| Age, mean (SD), years | 76 ± 10 | 84 ± 9 | 80 ± 10 | 76 ± 9 | 79 ± 9 |
| Female            | 56(47.1) | 7(25.0) | 13(52.0) | 6(21.4) | 38(40.4) |
| Comorbidity       |     |     |     |     |     |
| Hypertension      | 65(54.6) | 23(82.1) | 19(76.0) | 20(71.4) | 59(62.8) |
| COPD              | 22(18.5) | 11(39.3) | 4(16.0) | 5(17.9) | 24(25.5) |
| Diabetes          | 19(16.0) | 12(42.9) | 5(20.0) | 5(17.9) | 25(26.6) |
| Coronary artery disease | 27(22.7) | 12(42.9) | 7(28.0) | 6(21.4) | 26(27.7) |
| Stroke            | 22(18.5) | 6(21.4) | 8(32.0) | 6(21.4) | 9(9.6) |
| Anti-arrhythmic drug |     |     |     |     |     |
| β- blocker        | 45(37.8) | 7(25.0) | 11(44.0) | 14(50.0) | 28(29.8) |
| CCB               | 34(28.6) | 13(46.4) | 13(52.0) | 10(35.7) | 24(25.5) |
| Digoxin           | 18(15.1) | 0(0.0) | 0(0.0) | 2(7.1) | 1(1.1) |
| Amiodarone        | 21(17.6) | 1(3.6) | 6(24.0) | 3(10.7) | 7(7.5) |

AF, atrial fibrillation; AVB, atrioventricular block; PACs, premature atrial contraction; PVCs, premature ventricular contraction; ECG, electrocardiography; COPD, chronic obstructive pulmonary disease; CCB, calcium channel blockers.

FIGURE 3 | Participant selection and summary of ECG results. were analyzed, while only two (4.7%) limb lead data recordings were analyzed (Figure 3).

Compared with standard 12-lead ECG recordings, the AMAZFIT® detected AF, first-degree AVB, PACs, PVCs and normal ECG with similar accuracy (Table 2). An evaluation of the wearable dynamic ECG recorder for AF reported a sensitivity of 93.28%, a specificity of 95.35%, a PPV of 93.28%, an NPV of 95.35%, a PLR of 20.06 and an NLR of 0.07. This indicates that the smartwatch has excellent sensitivity and specificity for the detection of an irregular pulse from AF. The smartwatch also demonstrated superior sensitivity for PACs (84.00%) and PVCs (89.29%), respectively. However, the device demonstrated a low sensitivity for first-degree AVB (32.14%). The specificity of the AMAZFIT for first-degree AVB (97.72%), PACs (96.62%), PVCs (93.92%), and normal ECG (89.34%) detection was excellent.

We measured the HR of patients with AF using AMAZFIT® and 12-lead ECG. The intraclass correlation coefficients (ICC) of each device with a Bland-Altman plot of the induced SVT HR measurements are shown in Figure 4.

DISCUSSION

Our findings revealed that detection of arrhythmia with AMAZFIT® was feasible, and showed high diagnostic accuracy. The AMAZFIT® smart watch displayed excellent sensitivity for AF, PACs and PVCs, and a low sensitivity for first-degree AVB. In addition, we measured the HR of patients with AF using AMAZFIT® and with a 12-lead ECG. The results showed that the device can accurately measure the HR of AF similarly to the 12-lead ECG.

Arrhythmia is a common disease in the elderly, and AF is one of the world’s most common serious heart rhythm problems. AF increases the risk of stroke and heart failure in elderly patients, which in turn reduces the quality of life and increases the burden of care for elderly patients (15, 16). Although the 12-lead ECG remains the gold-standard diagnostic test for AF, a major challenge in diagnosis is the often paroxysmal nature of arrhythmia, particularly in its early stages. As such, periodic 24-h Holter monitoring is frequently used to determine the adequacy of rate control and guides medical therapy. The most commonly prescribed non-invasive AF monitors, including Holter and 30-day event monitors, have severe methodological shortcomings that result in low compliance, diagnosis delay, high cost, and adverse patient outcomes. Monitors with automated AF detection capabilities are approved for clinical use, but the invasive nature, cost, and technical limitations have limited their widespread application (17, 18).

There is increasing interest in the use of smartphone-based technology in arrhythmias especially in AF detection with numerous published feasibility and screening studies (19–21). Recently, several different types of smartwatches were used for cardiac rhythm analysis, including the Apple Watch, Kardia Band, Kardia Mobile and Simband (Samsung Electronics...
TABLE 2 | Diagnostic accuracy of AMAZFIT® against ECG.

| Diagnosis          | n   | Sensitivity (100%) | Specificity (100%) | Accuracy (100%) | PPV (100%) | NPV (100%) | PLR | NLR |
|--------------------|-----|-------------------|--------------------|-----------------|------------|------------|-----|-----|
| Arrhythmia         | 197 | 89.34             | 92.55              | 97.59           | 96.17      | 80.56      | 11.99 | 0.12|
| AF                 | 119 | 93.28             | 95.35              | 94.50           | 93.28      | 95.35      | 20.06 | 0.07|
| First-degree AVB   | 28  | 32.14             | 97.72              | 91.41           | 60.00      | 93.12      | 14.10 | 0.69|
| PACs               | 25  | 84.00             | 96.62              | 95.53           | 70.00      | 98.47      | 24.00 | 0.16|
| PVCs               | 28  | 89.29             | 93.92              | 93.47           | 60.98      | 98.80      | 14.69 | 0.11|
| Normal ECG         | 94  | 92.55             | 89.34              | 90.38           | 80.56      | 96.17      | 8.68  | 0.08|

PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; AF, atrial fibrillation; AVB, atrioventricular block; PACs, premature atrial contraction; PVCs, premature ventricular contraction; ECG, electrocardiography.

![FIGURE 4 | Bland-Altman plots of the heart ratio between the ECG and AMAZFIT®.](image)

The Apple Watch includes an irregular rhythm notification feature that detects PPG-based irregularity at rest, and can notify the user of potential AF (22). In our study, we demonstrated that the AMAZFIT® could reliably distinguish an irregular pulse between AF and other rhythms, including sinus rhythm, PACs, and PVCs. The AMAZFIT® for AF was found to have a sensitivity of 93.28%, a specificity of 95.35%, a PPV of 93.28%, an NPV of 95.35%, a PLR 20.06 and an NLR 0.07. Rajakariar et al. (23) reported sensitivity and specificity using the Kardia Band for identifying AF was 94.4 and 81.9% respectively, with positive and negative predictive values of 54.8 and 98.4%, respectively. These findings indicate that the AMAZFIT® has excellent sensitivity and specificity for the detection of an irregular pulse from AF. In this study, we also report the sensitivity, specificity and accuracy of the AMAZFIT® for PACs and PVCs. The results show that the AMAZFIT® can accurately discriminate between AF, PACs, PVCs and normal ECG. McManus et al. (24) reported that a smartphone-based app showed good accuracy for PACs, at 95.5%, and for discrimination of PVCs at 96.0%. The results of our study indicate that compared with standard 12-lead ECG recordings, the AMAZFIT® had excellent sensitivity and specificity for diagnosing arrhythmia such as AF, PACs and PVCs, in the older patients.

Because slower heartbeat rates can be observed in normal aging and in disease progression, bradycardia and conduction abnormalities are more commonly identified in the elderly (25). Atrioventricular block that occurs frequently or during exercise, can cause dizziness or symptoms of exertional intolerance. There have been no reports on the identification of atrioventricular block using smartwatches. In our study, we tried to explore the sensitivity and specificity of AMAZFIT® for the diagnosis of first-degree atrioventricular block. The results demonstrated that AMAZFIT® had a low sensitivity (32.14%) for the detection of an irregular pulse from first-degree AVB. However, the specificity of AMAZFIT® for first-degree AVB (97.72%) detection was excellent. Whether AMAZFIT® may serve as a useful complementary tool for first-degree AVB screening needs to be evaluated in a larger population-based study in the future.

Unlike other smartwatches, AMAZFIT® can collect single-lead ECG recordings from the chest lead in addition to limb single-lead ECG. We obtained chest lead data from all of the participants. While we collected arm lead data from only 43 (14.78%) participants, only two (4.7%) arm lead data recordings could be analyzed. Regrettably, the two recordings could not accurately reflect the heart rhythm of the patients. The advantages of AMAZFIT®, which collects single-lead ECG recordings of the chest lead, include convenience, small size, and long wearability. Accurate measurements with a smartwatch depend on an adequate blood flow and skin contact, and can be altered by the patient, movement of the device, environmental conditions, and ectopic beats (26). The population of this study includes adults 65 years and older. Elderly people may have loose and dry skin, which may affect the electrical conductivity of the skin, and reduce the quality of the AMAZFIT® performance.

As the use of wearable devices and direct-to-consumer medical devices increases in the general population, the potential abnormalities detected by these devices are brought to the attention of clinicians. For patients diagnosed with AF, proper clinical evaluation and confirmatory ECG testing are essential. New devices such as the AMAZFIT® are recommended to be integrated into patient care under physician supervision. Although important questions remain, wearable medical technology should be employed along with physician expertise.
CONCLUSIONS

Technological limitations may prevent the widespread use of AMAZFIT® arrhythmia screening in elderly patients, especially for first-degree AVB. However, AMAZFIT remains favorable compared with the conventional Holter monitoring system for symptomatic arrhythmia monitoring, despite the relatively low wearing rate in the elderly population. In the future, we look forward to more specialized arrhythmia screening tools. Cost-effective, convenient, reliable, and easy-to-apply tools for extended non-invasive AF detection would be helpful.

Study Strenghs

This diagnostic trial revealed that detection of arrhythmia with AMAZFIT® was feasible and showed a high diagnostic accuracy. The AMAZFIT® smart device displayed excellent sensitivity for AF, PACs and PVCs, and a low sensitivity for first-degree AVB. In addition, we measured the HR of patients with AF using AMAZFIT® and with a 12-lead ECG. The results showed that the device can accurately measure the HR of AF similarly to the 12-lead ECG.

Study Limitations

Our study has some limitations. First, the sample size was relatively small, especially the non-AF arrhythmia cohort. Second, we only measured the cardiac rhythm in very stable patients in a motionless state. Third, all of our patients were Asian; therefore, we did not consider whether the skin color could affect the accuracy of the AMAZFIT®.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board of West China Hospital of Sichuan University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

JW and MY designed and supervised the study. SZ collected the data, and wrote the article. HX, YC, YL, and NZ collected the data and assisted with wrote the article. XG was responsible for the statistical design of the study and for carrying out the statistical analysis. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke. (1991) 22:983–8. doi: 10.1161/01.STR.22.8.983
2. Spratt N, Wang Y, Levi C, Ng K, Evans M, Fisher J. A prospective study of predictors of prolonged hospital stay and disability after stroke J Clin Neurosci. (2003) 10:665–9. doi: 10.1016/j.jocn.2002.12.001
3. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study. Eur Heart J. (2013) 34:1061–7. doi: 10.1093/eurheartj/ehs469
4. Chugh SS, Havmoeller R, Narayan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation. (2014) 129:837–47. doi: 10.1161/CIRCULATIONAHA.113.005119
5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. (2016) 37:2893–962. doi: 10.5603/KP.2016.0172
6. Kervan WN, Ogbajege B, Black HR, Bravata DM, Chimowitz MI, Ettekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart association/American stroke association. Stroke. (2014) 45:2160–236. doi: 10.1161/STR.0000000000000224
7. Lau CP, Siu CW, Yiu KH, Lee KL, Chan YH, Tse HF. Subclinical atrial fibrillation and stroke: insights from continuous monitoring by implanted cardiac electronic devices. Europace. (2015) 17 (Suppl 2):i40–6. doi: 10.1093/europace/eu5235
8. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, et al. Screening for atrial fibrillation: a report of the af-screen international collaboration. Circulation. (2017) 135:1851–67. doi: 10.1161/CIRCULATIONAHA.116.026693
9. Cheung CC, Krahn AD, Andrade JG. The emerging role of wearable technologies in detection of arrhythmia. Can J Cardiol. (2018) 34:1083–7. doi: 10.1016/j.cjca.2018.05.003
10. Ip JE. Wearable devices for cardiac rhythm diagnosis and management. JAMA. (2019) 321:337–8. doi: 10.1001/jama.2018.20437
11. Tison GH, Sanchez JM, Ballinger B, Singh A, Olgin JE, Fletcher MJ, et al. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiol. (2018) 3:409–16. doi: 10.1001/jamacardio.2018.0136
12. Bumgarner JM, Lambert CT, Hussein AA, Cantillon DJ, Baranowski B, Wolski K, et al. Smartwatch algorithm for automated detection of atrial fibrillation. J Am Coll Cardiol. (2018) 71:2381–8. doi: 10.1016/j.jacc.2018.03.003
13. Desteghe L, Raymaekers Z, Lutin M, Vliegen J, Dilling-Boer D, Kooopman P, et al. Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace. (2017) 19:29–39. doi: 10.1093/europace/euw025
14. Nemati S, Ghassemi MM, Ambai V, Isakadze N, Levantsevych O, Shah A, et al. Monitoring and detecting atrial fibrillation using wearable technology. Conf Proc IEEE Eng Med Biol Soc. (2016) 2016:3394–7. doi: 10.1109/EMBC.2016.7591456
15. Prawer H, Voskoboinik A, Kaye DM, Kistler PM. Atrial fibrillation and heart failure—cause or effect? Heart Lung Circ. (2017) 26:967–74. doi: 10.1016/j.hlc.2017.05.117
16. Hahne K, Monnig G, Samol A. Atrial fibrillation and silent stroke: links, risks, and challenges. Vasc Health Risk Manag. (2012) 11:65–74. doi: 10.2147/VHRM.S81807
17. Ricci RP. Disease management: atrial fibrillation and home monitoring. Europace. (2013) 15 (Suppl 1):i35–i39. doi: 10.1093/europace/eut114
18. Purserfellner H, Sanders P, Pokushalov E, Di Bacco M, Dekker LRC, et al. Miniaturized Reveal LINQ insertable cardiac monitoring system: first-in-human experience. Heart Rhythm. (2015) 12:1113–9. doi: 10.1016/j.hrthm.2015.02.030
19. Rosen G, Vaid I, Hosseini SM, Kaadan MI, Rafaol A, Roka A, et al. Diagnostic accuracy of a novel mobile phone application for the detection...
and monitoring of atrial fibrillation. Am J Cardiol. (2018) 21:1187–91. doi: 10.1016/j.amjcard.2018.01.035
20. Tarakji KG, Wazni OM, Callahan T, Kanj M, Hakim AH, Wolski K, et al. Using a novel wireless system for monitoring patients after the atrial fibrillation ablation procedure: the iTransmit study. Heart Rhythm. (2015) 12:554–9. doi: 10.1016/j.hrthm.2014.11.015
21. Orchard J, Lowres N, Freedman SB, Ladak L, Lee W, Zwar N, et al. Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): a feasibility study. Eur J Prev Cardiol. (2016) 23:13–20. doi: 10.1177/2047487316670255
22. Apple Heart health notifications on your Apple Watch. Available online at: https://support.apple.com/zh-cn/HT208931 (accessed January 20, 2020).
23. Rajakariar K, Koshy AN, Sajeev JK, Nair S, Roberts L, Teh AW. Accuracy of a smartwatch based single-lead electrocardiogram device in detection of atrial fibrillation. Heart. (2020) 106:656–70. doi: 10.1136/heartjnl-2019-316084
24. McManus DD, Chong JW, Soni A, Saczynski JS, Esa N, Napolitano C, et al. PULSE-SMART: Pulse-based arrhythmia discrimination using a novel smartphone application. J Cardiovasc Electrophysiol. (2016) 27:51–7. doi: 10.1111/jce.12842
25. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. (2019) 74:e51–e156. doi: 10.1016/j.jacc.2018.10.044
26. Ip JE. Evaluation of cardiac rhythm abnormalities from wearable devices. JAMA. (2019) 321:1098–9. doi: 10.1001/jama.2019.1681

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Xian, Chen, Liao, Zhang, Guo, Yang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.